Zonisamide is a sulfonamide anticonvulsant approved for use as an adjunctive therapy in adults with partial-onset seizures, infantile spasm, mixed seizure types of Lennox–Gastaut syndrome, myoclonic, and generalized tonic clonic seizure.
CAT No: 10-101-130
CAS No:68291-97-4
Synonyms/Alias:AD-810; CI-912; PD-110843; 1,2-Benzisoxazole-3-methanesulfonamide; 3-(Sulfamoylmethyl)-1,2-benzisoxazole; Benzo[d]isoxazol-3-yl-methanesulfonamide
Zonisamide is a synthetic sulfonamide derivative recognized for its role as a small-molecule modulator of neuronal excitability and ion channel function. Structurally distinct due to its benzisoxazole ring and sulfonamide group, zonisamide exhibits significant influence on voltage-gated sodium and T-type calcium channels, making it a valuable research tool in neurobiology and pharmacology. Its unique chemical profile has prompted extensive investigation into mechanisms of neuronal signaling, synaptic modulation, and metabolic pathways involving sulfamoyl-containing compounds. Researchers leverage its multifaceted actions to elucidate fundamental aspects of nervous system physiology and to explore new directions in ion channel pharmacology.
Neuroscience research: Zonisamide is widely utilized in studies of neuronal excitability and synaptic transmission due to its capacity to modulate voltage-gated sodium and T-type calcium channels. By selectively inhibiting these channels, it enables researchers to dissect the molecular underpinnings of action potential generation and propagation in both central and peripheral neurons. This makes it an essential compound for investigations into excitatory and inhibitory balance, synaptic plasticity, and the pathophysiology of hyperexcitability disorders at the cellular and network levels.
Ion channel pharmacology: The compound serves as a critical probe in the characterization of ion channel subtypes and their pharmacological properties. Its dual action on sodium and calcium channels allows for the differentiation of channel-specific responses and the mapping of functional channel distributions in various neuronal populations. Zonisamide is frequently employed in electrophysiological assays, such as patch-clamp recordings, to evaluate the biophysical effects of channel inhibition and to screen for modulators of neuronal ion flux.
Neuroprotective mechanism studies: Researchers utilize zonisamide to investigate cellular mechanisms underlying oxidative stress, mitochondrial function, and neuroprotection. Evidence suggests that it can influence mitochondrial metabolism and modulate reactive oxygen species (ROS) production, offering a valuable model for examining the interplay between ion channel activity and neuronal survival. Such studies are instrumental in advancing the understanding of neurodegenerative processes and identifying potential molecular targets for neuroprotection.
Metabolic pathway elucidation: The sulfonamide structure of zonisamide provides a foundation for exploring the metabolism of sulfa-based compounds in biological systems. It is employed in enzymatic assays and metabolic profiling to track biotransformation pathways, conjugation reactions, and the formation of active or inactive metabolites in vitro. These studies contribute to a broader understanding of xenobiotic metabolism and the enzymatic processes governing drug biotransformation.
Analytical method development: Zonisamide is frequently used as a reference standard in the development and validation of analytical techniques, including high-performance liquid chromatography (HPLC), mass spectrometry, and capillary electrophoresis. Its distinct physicochemical properties make it suitable for optimizing detection parameters, calibrating instrumentation, and establishing quantification protocols in complex biological matrices. This application is vital for laboratories engaged in pharmacokinetic, toxicological, and environmental monitoring studies, ensuring robust and reproducible analytical performance.
Zonisamide is a modern antiepileptic drug (AED) that is distinguished from other AEDs by its unique structure and broad mechanistic profile. Preclinical studies have reported a range of potential mechanisms of action for zonisamide, such as blocking voltage-gated sodium channels, reduction of T-type calcium channel currents, and enhancement of gamma-aminobutyric acid (GABA)-mediated inhibition, which are indicative of its broad antiseizure effects. Zonisamide has a favorable linear pharmacokinetic profile, a long half-life, and a low incidence of protein-binding interactions with other AEDs.
Wilfong, A. A., & Willmore, L. J. (2006). Zonisamide–a review of experience and use in partial seizures. Neuropsychiatric disease and treatment, 2(3), 269.
The limitations of currently available therapies in addressing the non motor symptoms of Parkinson's disease (PD) have egged on the search for newer options. Zonisamide has been in use for epilepsy and it was serendipitously found to improve the symptoms of PD in a patient who had both epilepsy and PD. Thereafter, various trials were designed to assess the use of zonisamide in PD. The present article investigates the evidence for use of zonisamide in PD from the various clinical trials that were designed to address this issue. Furthermore, the article also summarizes the various mechanisms of its use in PD as described in various animal experiments.
Grover, N. D., Limaye, R. P., Gokhale, D. V., & Patil, T. R. (2013). Zonisamide: a review of the clinical and experimental evidence for its use in Parkinson's disease. Indian journal of pharmacology, 45(6), 547.
Epilepsy is one of the most common neurologic disorders, affecting about 50 million people around the world. It is recognized that around 50% of patients with newly diagnosed epilepsy become seizure-free with the first drug treatment, so the choice of first antiepileptic drug is crucial. This paper provides a comprehensive overview of zonisamide as monotherapy for partial seizures, with special attention to the possibility of a once-daily regimen. The available data suggest that zonisamide is an effective and well tolerated option as monotherapy.
Mula, M. (2013). Profile of once-daily zonisamide as monotherapy for treatment of partial seizures in adults. Drug design, development and therapy, 7, 397.
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More